Article
Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein.
Carcinogenesis - 1 Dec 1998
Chi W J, Doong S L, Lin-Shiau S Y, Boone C W, Kelloff G J, Lin J K
Abstract excerpt
Molecular epidemiological studies of populations at high risk for liver cancer have shown that hepatitis B virus (HBV) and aflatoxin B1 exposures are two major risk factors for this disease. Oltipraz is currently being considered for clinical trial to protect against aflatoxin B1-induced hepatocarcinogenesis based on its proven protective effect in many different animal models. In addition, oltipraz inhibits...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.